Two serum biomarkers (CCL11/eotaxin, IL-6) discriminate between CRMO, alternative diagnoses (acute leukemia, lymphoma, JIA, osteoarticular infections, and reactive or para-infectious arthritis), and healthy controls. Here, CCL11 is linked to lymphoma.